Review Article

Is PPARγ a Prospective Player in HIV-1-Associated Bone Disease?

Eoin J. Cotter, 1 Patrick W. Mallon, 2 and Peter P. Doran 1

1 Clinical Research Center, University College Dublin, Belfield, 4 Dublin, Ireland
2 School of Medicine & Medical Science, University College Dublin, Belfield, 4 Dublin, Ireland

Correspondence should be addressed to Eoin J. Cotter, eoin.cotter@ucd.ie

Received 30 June 2008; Revised 3 December 2008; Accepted 21 January 2009

Recommended by Lawrence Serfaty

Currently infection with the human immunodeficiency virus-1 (HIV-1) is in most instances a chronic disease that can be controlled by effective antiretroviral therapy (ART). However, chronic use of ART has been associated with a number of toxicities; including significant reductions in bone mineral density (BMD) and disorders of the fat metabolism. The peroxisome proliferator-activated receptor gamma (PPARγ) transcription factor is vital for the development and maintenance of mature and developing adipocytes. Alterations in PPARγ expression have been implicated as a factor in the mechanism of HIV-1-associated lipodystrophy. Both reduced BMD and lipodystrophy have been well described as complications of HIV-1 infection and treatment, and a question remains as to their interdependence. Interestingly, both adipocytes and osteoblasts are derived from a common precursor cell type; the mesenchymal stem cell. The possibility that dysregulation of PPARγ (and the subsequent effect on both osteoblastogenesis and adipogenesis) is a contributory factor in the lipid- and bone-abnormalities observed in HIV-1 infection and treatment has also been investigated. This review deals with the hypothesis that dysregulation of PPARγ may underpin the bone abnormalities associated with HIV-1 infection, and treats the current knowledge and prospective developments, in our understanding of PPARγ involvement in HIV-1-associated bone disease.

Copyright © 2009 Eoin J. Cotter et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Introduction

Aside from the serious effects on the cells of the immune system, HIV-1 infection and its treatment have been associated with disorders in other tissues, most notably bone [1, 2] and adipose [3–6] tissues, where reduced bone mineral density (BMD) and abnormalities of the lipid metabolism (lipodystrophy, dyslipidemia, and insulin resistance) have been described. In both disorders (particularly those of the adipose tissue), antiretroviral treatment is believed to play a major role, but the contribution of underlying HIV-1 infection has yet to be elucidated, and therefore cannot be ignored as a potential causative factor.

PPARγ is a nuclear membrane bound transcription factor which regulates a number of genes involved in adipogenesis from common precursor cells type (mesenchymal stem cells), maturation of preadipocytes, lipid accumulation, and maintenance of adipogenic phenotype [7, 8]. As such, it is not surprising that a number of recent studies have indicated that certain drugs known to be associated with lipodystrophy dysregulate PPARγ [9, 10]. The involvement of PPARγ in HIV-1-associated bone disease is an area that has been little studied to date; however numerous studies suggest that PPARγ plays a role in conditions such as osteoporosis in the absence of HIV-1 or ART, and increased adipocyte content of osteoporotic bone has been reported [10–12]. In addition, osteoblasts—the cells responsible for depositing bone—are derived from mesenchymal stem cells, and evidence suggests that the balance of PPARγ and the pro-osteogenic runt-related transcription factor-2 (RUNX-2) is a key in the determination of mesenchymal stem cell fate [13–15] (see Figure 1). This review will introduce the current knowledge of the role of PPARγ in bone biology in normal and disease states, and discuss its potential as a mechanism for HIV-1-associated bone disease.

2. HIV-1-Associated Bone Disease

Osteoporosis is defined as a reduction in the bone mass and disruption of the microarchitecture of the bone which leads to a greatly increased risk of fractures, while osteopenia
is a lesser reduction in bone density and strength which may remain asymptomatic, but can precede actual osteoporosis. The world health organization (WHO) definitions specify t-scores between −1 and −2.5 as being indicative of osteopenia, while t-scores of less than −2.5 are indicative of osteoporosis [16]. Fractures resulting from osteoporosis affect one in two women and one in five men over the age of 50, and are a significant financial burden to health services, with an estimated combined annual cost of 30 billion Euro in the EU [17].

As will be discussed further, bone remodeling is dependent on the opposing functions of two cell types, osteoblasts, which make new bone (bone formation), and osteoclasts, which destroy old bone (bone resorption). Therefore, the balance between the number and activity of osteoclasts and osteoblasts is crucial in normal bone homeostasis; the perturbation of which can directly lead to increased bone fragility and fracture risk. Two important molecules: macrophage colony-stimulating factor (M-CSF) and receptor for activation of nuclear factor-kappa B ligand (RANKL) produced from osteoblast/stromal cells regulate the differentiation, function, and survival of osteoclasts, while the transcription factors, RUNX-2 and Osterix, have been reported to regulate osteoblast differentiation [18].

2.1. HIV-1 Infection and Bone Disease. Bone metabolism in HIV-infected individuals has been studied since the late 1980s, although the number of early studies is somewhat limited. Before the widespread use of highly active ART, studies indicated that bone mineral metabolism was only minimally affected in HIV-infected patients. Serrano et al. assessed histomorphometry in HIV-positive patients and found that parameters of histomorphometry such as serum osteocalcin were found to be lower in patients who, according to the Centers for Disease Control (CDC) classification, had greater disease severity [19]. Paton et al. reported that 45 HIV-infected patients had marginally lower BMD at the lumbar spine. None of the patients had reduced BMD to levels associated with a diagnosis of osteoporosis [20]. More recently however, it became clear that reduced BMD is also frequent in the absence of therapy [21–24]. In a study by McGowan et al., the prevalence of osteopenia among antiretroviral-naive HIV-positive individuals to be approximately 28%, which is approximately 50% greater than the expected incidence in the general, uninfected population [25]. Studies which have included patients with more advanced HIV disease who have received treatment for longer periods have reported prevalence of 40% to 50% [26, 27], placing reduced BMD among the most common HIV-1-associated metabolic toxicities. Amiel et al. also assessed BMD in 48 HIV-infected treatment-naive patients, 49 HIV-infected patients on protein inhibitors, 51 HIV-infected patients on no-protein inhibitors, and 81 HIV-uninfected control subjects. The results showed a significant decrease of BMD (9%) in all HIV-infected patients compared to the control subjects, occurring concurrently with a lower bone alkaline phosphatase and higher urinary cross-laps/Cr [28].

The clinical impact of this reduced BMD is beginning to be examined; recent studies in a large American health care system, involving 8526 HIV infected patients and over 2 million control subjects, demonstrated that the prevalence of any fracture type was significantly higher in the HIV-infected population (2.87 versus 1.77 fractures/100 persons, \( P = .002 \)). This study did not specify the treatment status of their subjects, but the data suggests that HIV-1-related fractures are a significant and growing clinical issue [29].

2.2. Antiviral Treatment and Bone Diseases. Antiretroviral treatment (ART) is a complex therapeutic regimen, in which patients typically take 2–3 agents selected from an array of 30 approved antiretroviral agents. ART, in general, comprises of two major therapeutic strategies: a protease inhibitor- (PI-) based regimen and a nucleoside reverse transcriptase inhibitor- (NRTI-) based regimen. The PI-based regimen uses one or two PIs combined with two NRTIs, whereas the NRTI-based regimen uses two NRTIs combined with one non-nucleoside reverse transcriptase inhibitor (NNRTI). With more effective therapies as a result of HAART, the prevalence of HAART-associated bone diseases has increased [30].

A higher incidence of reduced BMD has been clinically associated with both PI and NRTI uses. Tebas et al. determined that in HIV-1 patients receiving PIs about 50% of the patients had osteopenia and other 21% had osteoporosis [31]. This incidence is significantly increased
compared to patients without therapy or normal controls. Studies by Moore et al. confirmed that 71% of HIV-infected patients on PI therapy had reduced BMD [32]. Similarly, Carr et al. reported that 3% of 44 HIV-infected patients receiving NRTIs developed osteoporosis and 22% developed osteopenia [33], while in a study examining HIV-1-infected men Mallon determined a reduction in BMD beginning at 48 weeks post initiation of treatment [6]. Tsekes et al. determined BMD and whole body fat by dual energy X-ray absorbance (DEXA) of HIV-infected patients receiving zidovudine and other NRTIs and found significant decreases in both body fat and BMD [34]. In addition, the recent analysis by Brown and Qaqish [35] also reported 2.5-fold increased odds of reduced BMD in ART-treated patients compared with ART-naive patients (95% CI 1.8, 3.7). However, most studies are in agreement that traditional risk factors for osteoporosis, such as ethnic variations, female sex, increasing age, low body mass index, and time since menopause, are all independent predictors of osteopenia/osteoporosis [36–40].

In addition, it has been noted that HIV-infected patients have an increased risk for osteonecrosis of the hip [41]. Keruly et al. reported 15 cases of avascular hip necrosis in HIV-infected patients and suggested that the incidence of osteonecrosis in HIV-infected patients was higher than the general HIV-negative population [42]. It is not known whether this phenomenon is attributable to HIV-1 infection itself, HAART, or other HIV-associated complications.

The mechanisms by which either HIV-1 or its treatment induces reduced BMD are as yet unclear, and several researchers have suggested that reduced vitamin D levels observed in HIV-1-infected patients, and particularly the reduced levels of the biologically active metabolite 1,25(OH)2D (which is the natural ligand for the vitamin D receptor (VDR)), may contribute to reduced BMD [43]. Studies have demonstrated that the level of 1,25(OH)2D in HIV-1-infected patients is between 5 and 50% lower than that in infected patients [24, 44, 45]. In addition, studies have indicated that patients receiving treatment are more likely to have greater reductions in 1,25(OH)2D, with a recent Dutch study suggesting that NNRTI treatment may increase the risk of vitamin D deficiency [46, 47]. In addition, the latter study demonstrated that patients receiving treatment also have increased parathyroid hormone (PTH) levels, increasing the potential risk of reduced bone mass.

In short, HIV-1-associated bone disorders are a significant and increasingly well-defined clinical issue. However, the molecular basis underpinning these clinical observations remains to be fully explained.

3. PPARγ: Mediator of Development and Disease in Bone Biology

As discussed previously, maintenance of bone homeostasis is mediated through a balance of osteoblast-mediated bone deposition and osteoclast-mediated bone resorption. The continued production of these cells from stromal (mesenchymal) and hematopoietic (monocyte) precursors, respectively, is an essential component in the maintenance of BMD. Stromal progenitor or mesenchymal stem cells are multipotent cells, capable of producing cells of a number of different lineages, including osteoblasts and adipocytes [47–49].

Since the early 1990s, researchers have hypothesized that a “see-saw” relationship exists in the bone marrow cavity, where production of adipocytes from stromal precursors is at the expense of osteoblast production and vice versa [50, 51]. This theory is born out by a clinically observed phenomenon, such as the increased adipocyte content of osteoporotic and aging bone [51–53] as well as studies where agents inducing adipocyte production reduced osteoblast number [49, 50]. Likewise, treatment of bone marrow stromal cells with bone morphogenic proteins (BMPs) resulted in reduced formation of adipocytes [53]. Adipocytes can also produce secreted factors such as leptin and estrogen, which can positively regulate bone mass [13, 54, 55], further underlining the interrelated nature of bone and fat development (see Figure 1).

PPARs are ligand-activated nuclear hormone receptors which stimulate expression of genes containing peroxisome proliferator response elements (PPREs) [53, 54]. There are three principal members of this family, PPARα, PPARδ, and PPARγ, activation of which stimulates genes involved in fatty acid oxidation, uncoupling of respiration toward heat production (thermoregulation) and terminal adipocyte differentiation (including intracellular lipid accumulation), respectively, (see Table 1) [49, 50, 55–59].

The activity of PPARγ and RUNX-2 is a key to our understanding of the relationship between fat and bone. Activity of the RUNX-2 transcription factor is not only essential for maintenance of osteoblast phenotype, but it is also involved in driving the differentiation of osteoblasts from mesenchymal stem cells [11–14], while activity of PPARγ in mesenchymal stem cells induces differentiation into adipocytes. The eventual phenotype of the differentiating cell is generally considered to be controlled by an antagonistic balance between RUNX-2 and PPARγ [13, 14]. Studies have demonstrated, for example, that activation of PPARγ using pharmacological agents can lead to decreased bone mass in vivo, while mice lacking the PPARγ gene display increased bone mass and an inability to develop adipocytes [59–61]. Indeed, even in the eventual mature cell, the function can be altered by dysregulating this balance, with in vivo studies using a mouse model demonstrating reduced bone formation rate and suppression of RUNX-2 in osteoblasts in which PPARγ had been activated [61], while Kim et al. have demonstrated that activation of PPARγ induces death through a MAPK-dependant mechanism in osteoblastic cells [62].

PPARγ deficient mice (having a mutation in the PPARγ2 locus) have been generated and display a “lipodystrophic” phenotype, which occurs concurrently with increased bone mass, to the point where the bone marrow is almost completely occluded and hematopoiesis moves to extramedullary sites, such as the spleen [61, 63]. Recently, our understanding of the roles of PPARγ in numerous physiologic processes, including the bone/fat paradigm, has been furthered by the development of the thiazolidinedione (TZD) family of
PPARγ ligands, such as netoglitazone, pioglitazone, rosiglitazone, and GW0072 [64–67]. Studies have demonstrated that treatment of murine osteoblasts with netoglitazone and GW0072 can block osteoblast differentiation, without inducing adipogenesis [62, 64], while in vivo studies have demonstrated that rosiglitazone, a ligand with higher affinity for PPARγ, decreased bone mineral density, bone formation rate, and trabecular bone volume, while increasing adipogenesis [65, 67]. Further studies on ovariectomized rats revealed that these effects are mediated in part by the suppression of the RUNX-2 transcription factor [67], giving further strength to the argument that an antagonistic relationship between PPARγ and RUNX-2 governs bone and fat formation. Indeed, Hong et al. have demonstrated that shared coactivator protein, TAZ, accounts in some part for this relationship, in that it coactivates RUNX-2 and bone formation, while suppressing PPARγ [68].

3.1. PPARγ in HIV-1-Associated Lipodystrophy. ART is associated with changes in fat metabolism, broadly termed lipodystrophy (changes in fat distribution) or lipoatrophy (atrophy of adipose tissue). Severe forms of lipodystrophy are a major cosmetic concern, and can lead to suboptimal adherence to therapy. In addition, lipoatrophy is associated with markers of cardiovascular risk, such as insulin resistance and dyslipidemia [5].

In vitro, expression of PPARγ is decreased by exposure to anti-HIV-1 PI and NRTI drugs. In differentiating adipocytes, exposure to nelfinavir, saquinavir, and ritonavir at 10 μM concentrations resulted in decreased adipogenesis and expression of the PPARγ-mediated mRNA encoding aP2 and lipoprotein lipase (LPL) [10]. Similar effects on PPARγ expression were observed in 3T3-F442A adipocyte cells exposed to 10–50 μM indinavir [69], while studies by the same group have also demonstrated that the nuclear association of the PPARγ regulator SREBP-1 is reduced by treatment with indinavir [70]. In mature adipocytes, inhibition of PPARγ function by expression of a dominant negative PPARγ isoform results in decreased accumulation of intracellular triglyceride, decreased cell size, and decreased expression of genes involved in both fatty acid and glucose metabolism, including the glucose transporter GLUT-4 [71]. In lipoatrophic mice, ablation of PPARγ activity in liver resulted in hepatic steatosis, hypertriglyceridemia, and muscle insulin resistance [72]. Many of these features are shared by PI-treated patients with HIV-1-associated lipodystrophy.

In vivo, patients with lipodystrophy had lower adipose tissue expression of both PPARγ and PPARδ than those without lipodystrophy. This was accompanied by decreases in a number of PPARγ-responsive downstream genes including LPL and GLUT-4 [73, 74]. In studies by Mallon, NRTI treatment of non-HIV-1-infected subjects (either stavudine/lamivudine or zidovudine/lamivudine for six weeks) resulted in reduced PPARγ expression in adipose tissue (alongside alterations in transcription of mitochondrial DNA, and upregulation of genes associated with mitochondrial transcriptional regulation), although in this study the effects on overall fat mass were not determined [9].

In patients with type 2 diabetes, exposure to TZD, which act as PPARγ ligands, resulted in increased expression of PPARγ-target genes such as LPL and fatty acid synthase (FAS) in subcutaneous adipose tissue biopsies, without increasing expression of PPARγ itself [71]. However, studies utilizing TZD to treat lipodystrophy have produced variable, and at best, modest results [75–78]. More recently, van Wijk et al. demonstrated that rosiglitazone treatment, compared to treatment with metformin, increased subcutaneous abdominal and visceral abdominal fat in lipodystrophy, however this was a small study (n = 39), was not blinded or placebo controlled, and did not measure clinical outcomes [79].

The weight clinical and scientific evidence suggests that HIV-1/ART-associated lipid abnormalities occur largely as

| Table 1: PPARγ-regulated genes involved in adiogenesis, glucose uptake, and thermoregulation (↑ positive regulation; ↓ negative regulation). |
|---------------------------------|---------------------------------|---------------------------------------------------------------|
| PPARγ-regulated genes          | Tissue/cell type                | Function                                                      |
|---------------------------------|---------------------------------|---------------------------------------------------------------|
| CCAT enhancer binding protein α  | Adipose/preadipose tissue      | Transcription factor. CDK2/4 inhibition-cell cycle arrest      |
| (CEBPα) [71]†                  |                                 | Associated with globule membrane, early marker of adipocyte    |
| Adipose differentiation related | Adipose/preadipose tissue      | differentiation                                                |
| protein (ADRP) [50]†            |                                 |                                                               |
| Lipoprotein lipase [49]†        | Vascular endothelium, heart,   | Lipid hydrolysis from lipoproteins                             |
|                                 | muscle, adipose                 |                                                               |
| Adiponectin [49]†               | Adipose tissue (secreted)       | Fatty acid catabolism                                          |
| Adipocyte protein 2 (aP2/FABP4) | Adipocytes/macrophages          | Intercellular lipid transport                                  |
| [49]†                           |                                 |                                                               |
| Tumour suppressor candidate 5   | Preadipose/adipose tissue       | Associated with entry into the later stages of adipogenesis   |
| (TUSC5) [56]†                   |                                 |                                                               |
| Glucose transporters 4 (GLUT) 4 | Wide tissue distribution        | Insulin stimulated glucose uptake                              |
| [57]†                           |                                 |                                                               |
| Uncoupling proteins 1-3 (UCP 1-3)| Adipose tissue, skeletal muscle,| Thermogenesis/thermoregulation                                 |
| [58]†                           | liver                           |                                                               |

*P* values are as indicated in the figure. The *P* values for differences are derived from the ANOVA test and Tukey’s post-hoc test or *t*-test as stated in the figure.
a result of treatment rather than infection. However, a recent study raised the possibility that there may also be a viral component; Shrivastav et al. [80] demonstrated that treatment with the HIV-1 accessory viral protein R (Vpr) could suppress PPARγ-induced transactivation in 3T3-L1 murine adipocyte cells, with a consequent inhibition of adipocyte differentiation. Vpr is a 96-amino-acid accessory protein, which is packaged in the viral capsid, and is found in the nucleus early after cell infection [81, 82]. Among the functions of Vpr is its ability to act as a transcriptional activator of viral and cellular promoters [83–86]. Vpr enhances the activity of steroid hormone receptors, including the glucocorticoid receptor (GR), which Vpr can bind via its LXXLL motif [85]. Studies involving cotransfection with constructs expressing wild type and mutant (LXXLL null) Vpr constructs with reporter constructs containing the PPRE demonstrated that this phenomenon was dependent on the LXXLL motif. Further experiments demonstrated that the GR did not play a role, and that Vpr and PPARγ interacted directly in living cells. The authors of this study hypothesize that in vivo circulating Vpr, or Vpr produced as a result of direct infection of adipocytes, could suppress differentiation of preadipocytes in a PPARγ dependent manner with obvious consequences for the development of lipodystrophy and insulin resistance [80].

3.2. PPARγ in HIV-1-Associated Bone Disease. In contrast to the clearly defined role for PPARγ in HIV-1/ART-associated lipid abnormalities, few studies have focused on its potential impact in HIV-1/ART-associated bone abnormalities.

To date, studies into mechanism of reduced bone density have been understandably focused on two distinct strands, namely, the effects on osteoblast and osteoclast number and function. In the case of OC research, several studies have demonstrated that osteoclast activity can be altered in vitro by treatment with both ritonavir and HIV-1 gp120 [87, 88]; Jain et al. demonstrated that osteoclast activity, measured using a rat neonatal calvaria assay, increased in the presence of nelfinavir, indinavir, saquinavir, or ritonavir, while lopinavir and amprenavir did not increase osteoclast activity. In addition, Pan et al. reported a significant increase in markers of osteoclastogenesis (namely, the activity of the tartric acid phosphatase (TRAP) promoter and the NF-κb transcription factor) in RAW264.7 (mouse leukemic monocyte macrophage cell line cells) and primary mouse osteoclast precursors treated with the NRTI zidovudine [89]. This same group has more recently reported that the NRTIs ddI and lamivudine also induced osteoclastogenesis in vitro and osteopenia in an in vivo mouse model [90].

Similarly, osteoblast-based studies have produced some interesting data. Clinically, Serrano et al. reported reduced numbers of osteoclasts in HIV patients; a phenomenon occurring along side-reduced serum osteocalcin levels and bone formation rate [19]. Previous and ongoing in vitro studies by our own group have demonstrated that osteoblast activity (as measured by calcium deposition and alkaline phosphatase activity) can be reduced by a number of antiretroviral drugs (including both nelfinavir and indinavir). In addition, these studies identified tissue inhibitor of metalloproteinase-3 (TIMP-3) as a mechanism for this observed loss in osteoblast function [91]. Further studies by our group demonstrated that treatment with the HIV-1 proteins p55-gag and gp120 reduced osteoblast activity in conjunction with reduction RUNX-2 transcription factor activity [92]. Interestingly, gp120 both decreased RUNX-2 activity and increased PPARγ. Furthermore, our studies investigating the effect of HIV-1 proteins on mesenchymal stem cell differentiation have suggested that the proteins p55 and REV alter both mesenchymal stem cell osteoblastic differentiation and RUNX-2/PPARγ signalling in nondifferentiating mesenchymal stem cells [93].

Although these studies used a somewhat simplistic model of HIV-1 exposure, given the evidence of the impact of PPARγ on normal bone biology, and the observation that it can be perturbed in HIV-1-associated lipodystrophy, it is tempting to interpret these results as being suggestive of PPARγ playing a role in HIV-1-mediated bone disease. However, there is an obvious stumbling block for this hypothesis, namely, that if increased PPARγ activity in mesenchymal stem cell and osteoblasts could result in reduced bone mass, it would surely also increase fat mass. This picture is further complicated, as previously discussed studies have demonstrated that treatment of non-HIV-1-infected subjects with NNRTIs resulted in reduced PPARγ expression in adipose tissue [9], while in vitro studies with 3T3-F442A cells have demonstrated that both PPARγ expression and its association with SREBP-1 are reduced by treatment with vindinavir [69, 70]. However, different processes may govern fat redistribution in different tissues, with gain in visceral fat and loss of subcutaneous fat. In addition, at least one ex vivo study suggests that both markers of adipocyte and osteoblastic differentiation are significantly reduced in human mesenchymal stem cells treated with a subset of protease inhibitors (particularly nelfinavir and saquinavir) [94], while HIV-1 patients receiving the NRTI zidovudine were shown to have reduced both BMD and whole body fat [33]. Could it be that contributing to both HIV-1/ART-associated bone and lipid disorders is an underlying deregulation of mesenchymal stem cell function combined with separate effects on adult or partially differentiated cells?

4. Conclusion

The importance of PPARγ in both bone and fat metabolism has been clearly demonstrated, and while a role for PPARγ in the lipid abnormalities associated with HIV-1 and its treatment is emerging, its involvement in HIV-1-associated bone disease remains unclear. Given the common origin of both adipocytes and osteoblasts from mesenchymal stem cell, and the demonstrated effect of increased PPARγ expression on bone in vitro and in vivo, we hypothesize a potential role for PPARγ in the reduced bone mass associated with HIV-1 infection and treatment. It may be possible that HIV-1 infection and/or treatment, through dysregulating PPARγ (and possibly also RUNX-2) activity in undifferentiated stromal cells, or in partially differentiated preosteoblast
and preadipocyte cells, can reduce the eventual number or functional capacity of the adult cell types.

In order to further investigate this hypothesis, it may be worthwhile to conduct ex vivo experiment on primary mesenchymal stem cells collected from HIV-1 patients. The expression and activity of PPARγ and differentiation potential of these cells could be assessed and compared to those of cells harvested from uninfected individuals, and the data gathered used to generate a new model of HIV-1/PPARγ/mesenchymal stem cell interactions.

It is clear that further studies are necessary to more fully describe the role of PPARγ in the setting of HIV-1-associated bone disease and its interplay with vascular and fat disorders.

References

[1] W. G. Powderly, “Long-term exposure to lifelong therapies,” Journal of Acquired Immune Deficiency Syndromes, vol. 29, supplement 1, pp. S28–S40, 2002.

[2] N. S. Chew, P. P. Doran, and W. G. Powderly, “Osteopenia and osteoporosis in HIV: pathogenesis and treatment,” Current Opinion in HIV and AIDS, vol. 2, no. 4, pp. 318–323, 2007.

[3] A. Milinkovic and E. Martinez, “Current perspectives on HIV-associated lipodystrophy syndrome,” Journal of Antimicrobial Chemotherapy, vol. 56, no. 1, pp. 6–9, 2005.

[4] K. Fisher, “Wasting and lipodystrophy in patients infected with HIV: a practical approach in clinical practice,” AIDS Reader, vol. 11, no. 3, pp. 132–147, 2001.

[5] A. Milinković, “HIV-associated lipodystrophy syndrome,” Collegium Antropologicum, vol. 30, supplement 2, pp. 59–62, 2006.

[6] P. W. Mallon, J. Miller, D. A. Cooper, and A. Carr, “Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy,” AIDS, vol. 17, no. 7, pp. 971–979, 2003.

[7] E. D. Rosen and B. M. Spiegelman, “Molecular regulation of adipogenesis,” Annual Review of Cell and Developmental Biology, vol. 16, pp. 145–171, 2000.

[8] S. Heikinnen, J. Auwerx, and C. A. Argmann, “PPARγ in human and mouse physiology,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 999–1013, 2007.

[9] P. W. Mallon, P. Unemori, R. Sedwell, et al., “In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA,” Journal of Infectious Diseases, vol. 191, no. 10, pp. 1686–1696, 2005.

[10] J. M. Lenhard, E. S. Furline, R. G. Jain, et al., “HIV protease inhibitors block adipogenesis and increase lipolysis in vitro,” Antiviral Research, vol. 47, no. 2, pp. 121–129, 2000.

[11] J. M. Gimble, S. Zvonic, Z. E. Floyd, M. Kassem, and M. E. Nuttall, “Playing with bone and fat,” Journal of Cellular Biochemistry, vol. 98, no. 2, pp. 251–266, 2006.

[12] L.-J. Zhao, H. Jiang, C. J. Papasian, et al., “Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis,” Journal of Bone and Mineral Research, vol. 23, no. 1, pp. 17–29, 2008.

[13] X. Shi, M. Hamrick, and C. M. Isales, “Energy balance, myostatin, and GIIZ: factors regulating adipocyte differentiation in belly and bone,” PPAR Research, vol. 2007, Article ID 92501, 12 pages, 2007.

[14] A. I. Caplan, “Mesenchymal stem cells,” Journal of Orthopaedic Research, vol. 9, no. 5, pp. 641–650, 1991.

[15] C. A. Gregory, D. J. Prockop, and J. L. Spees, “Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation,” Experimental Cell Research, vol. 306, no. 2, pp. 330–335, 2005.

[16] K. E. S. Poole and J. E. Compston, “Osteoporosis and its management,” British Medical Journal, vol. 333, no. 7581, pp. 1251–1256, 2006.

[17] NIH Consensus Development Panel, “Osteoporosis prevention, diagnosis, and therapy,” Journal of the American Medical Association, vol. 285, no. 6, pp. 785–795, 2001.

[18] S. L. Teitelbaum, “Bone resorption by osteoclasts,” Science, vol. 289, no. 5484, pp. 1504–1508, 2000.

[19] S. Serrano, M. L. Mariniø, J. C. Soriano, et al., “Bone remodeling in human immunodeficiency virus-1-infected patients. A histomorphometric study,” Bone, vol. 16, no. 2, pp. 185–191, 1995.

[20] N. I. J. Paton, D. C. Macallan, G. E. Griffin, and M. Pazianas, “Bone mineral density in patients with human immunodeficiency virus infection,” Calcified Tissue International, vol. 61, no. 1, pp. 30–32, 1997.

[21] K. Mondy, W. G. Powderly, S. A. Claxton, et al., “Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection,” Journal of Acquired Immune Deficiency Syndromes, vol. 38, no. 4, pp. 426–431, 2005.

[22] H. Knobel, A. Guelar, G. Vallecillo, X. Nogués, and A. Diez, “Osteopenia in HIV-infected patients: is it the disease or is it the treatment?” AIDS, vol. 15, no. 6, pp. 807–808, 2001.

[23] A. Lawal, E. S. Engelso, J. Wang, S. B. Heymsfield, and D. P. Kotler, “Equivalent osteopenia in HIV-infected individuals studied before and during the era of highly active antiretroviral therapy,” AIDS, vol. 15, no. 2, pp. 278–280, 2001.

[24] J. Teichmann, E. Stephan, U. Lange, et al., “Osteopenia in HIV-infected women prior to highly active antiretroviral therapy,” Journal of Infectious Disease, vol. 46, no. 4, pp. 221–227, 2003.

[25] I. McGowan, A. Cheng, S. Coleman, A. Johnson, and H. Genant, “Assessment of bone mineral density (BMD) in HIV-infected antiretroviral-therapy-naive patients,” in Proceedings of the 8th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill, USA, February 2001, abstract no. 628.

[26] J. Hoy, J. Hudson, M. Law, and D. A. Cooper, “Osteopenia in a randomized, multicenter study of protease inhibitor (PI) substitution in patients with the lipodystrophy syndrome and well-controlled HIV viremia,” in Proceedings of the 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif, USA, January-February 2000, abstract no. 208.

[27] K. Mondy, K. Yarasheski, W. G. Powderly, et al., “Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals,” Clinical Infectious Diseases, vol. 36, no. 4, pp. 482–490, 2003.

[28] C. Amiel, A. Osterlag, L. Slama, et al., “BMD is reduced in HIV-infected men irrespective of treatment,” Journal of Bone and Mineral Research, vol. 19, no. 3, pp. 402–409, 2004.

[29] V. A. Triant, T. T. Brown, H. Lee, and S. K. Grinspoon, “Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 9, pp. 3499–3504, 2008.

[30] G. Pan, Z. Yang, S. W. Ballinger, and J. M. McDonald, “Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS,” Annals of the New York Academy of Sciences, vol. 1068, pp. 297–308, 2006.
[31] P. Tebas, W. G. Powderly, S. Claxton, et al., “Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy,” AIDS, vol. 14, no. 4, pp. F63–F67, 2000.

[32] A. L. Moore, A. Vashisht, C. A. Sabin, et al., “Reduced bone mineral density in HIV-positive individuals,” AIDS, vol. 15, no. 13, pp. 1731–1733, 2001.

[33] A. Carr, J. Miller, J. A. Eisman, and D. A. Cooper, “Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy,” AIDS, vol. 15, no. 6, pp. 703–709, 2001.

[34] G. T. Allison, M. P. Bostrom, and M. J. Glesby, “Osteonecrosis of bone marrow progenitors, ” Osteoporosis International, vol. 16, no. 2, pp. 101–102, 2004.

[35] W. Liao, M. T. A. Nguyen, T. Yoshizaki, et al., “Suppression of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice,” Endocrinology, vol. 154, no. 6, pp. 3513–3524, 2003.

[36] A. L. Moore, A. Vashisht, C. A. Sabin, et al., “Reduced bone mineral density in HIV-positive individuals: e

[37] P. Tebas, W. G. Powderly, S. Claxton, et al., “Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy,” AIDS, vol. 14, no. 4, pp. F63–F67, 2000.

[38] A. L. Moore, A. Vashisht, C. A. Sabin, et al., “Reduced bone mineral density in HIV-positive individuals,” AIDS, vol. 15, no. 13, pp. 1731–1733, 2001.

[39] A. Carr, J. Miller, J. A. Eisman, and D. A. Cooper, “Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy,” AIDS, vol. 15, no. 6, pp. 703–709, 2001.

[40] G. T. Allison, M. P. Bostrom, and M. J. Glesby, “Osteonecrosis of bone marrow progenitors, ” Osteoporosis International, vol. 16, no. 2, pp. 101–102, 2004.

[41] W. Liao, M. T. A. Nguyen, T. Yoshizaki, et al., “Suppression of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice,” Endocrinology, vol. 154, no. 6, pp. 3513–3524, 2003.

[42] A. L. Moore, A. Vashisht, C. A. Sabin, et al., “Reduced bone mineral density in HIV-positive individuals: e

[43] P. Tebas, W. G. Powderly, S. Claxton, et al., “Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy,” AIDS, vol. 14, no. 4, pp. F63–F67, 2000.

[44] A. L. Moore, A. Vashisht, C. A. Sabin, et al., “Reduced bone mineral density in HIV-positive individuals,” AIDS, vol. 15, no. 13, pp. 1731–1733, 2001.

[45] A. Carr, J. Miller, J. A. Eisman, and D. A. Cooper, “Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy,” AIDS, vol. 15, no. 6, pp. 703–709, 2001.

[46] G. T. Allison, M. P. Bostrom, and M. J. Glesby, “Osteonecrosis of bone marrow progenitors, ” Osteoporosis International, vol. 16, no. 2, pp. 101–102, 2004.

[47] M. E. Nuttall and J. M. Gimble, “Controlling the balance between osteoblastogenesis and adipogenesis and the consequent therapeutic implications,” Current Opinion in Pharmacology, vol. 4, no. 3, pp. 290–294, 2004.

[48] J. N. Beresford, J. H. Bennett, C. Devlin, P. S. Lebov, and M. E. Owen, “Evidence for an inverse relationship between the differentiation of adipocytic and osteogenic cells in rat marrow stromal cell cultures,” Journal of Cell Science, vol. 102, no. 2, pp. 341–351, 1992.

[49] M.-A. Dorheim, M. Sullivan, V. Dandapani, et al., “Osteoblastic gene expression during adipogenesis in hematopoietic supporting murine bone marrow stromal cells,” Journal of Cellular Physiology, vol. 154, no. 2, pp. 317–328, 1993.

[50] S. Verma, J. H. Rajaratnam, J. Denton, J. A. Hoyland, and R. J. Byers, “Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis,” Journal of Clinical Pathology, vol. 55, no. 9, pp. 693–698, 2002.

[51] P. Meunier, J. Aaron, C. Edouard, and G. Vignon, “Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies,” Clinical Orthopaedics and Related Research, vol. 80, pp. 147–154, 1971.

[52] J. M. Gimble, C. Morgan, K. Kelly, et al., “Bone morphogenetic proteins inhibit adipocyte differentiation by bone marrow stromal cells,” Journal of Cellular Biochemistry, vol. 58, no. 3, pp. 393–402, 1995.

[53] M. W. Hamrick, “Invited perspective: leptin and bone—a consensus emerging?” Bonekey Osteovision, vol. 4, pp. 99–107, 2007.

[54] M. W. Hamrick, M. A. Della-Fera, Y.-H. Choi, C. Pennington, D. Hartzell, and C. A. Baile, “Leptin treatment induces loss of bone marrow adipocytes and increases bone formation in leptin-deficient ob/ob mice,” Journal of Bone and Mineral Research, vol. 20, no. 6, pp. 994–1001, 2005.

[55] P. J. Oort, C. H. Warden, T. K. Baumann, T. A. Knotts, and S. H. Adams, “Characterization of Tusc5, an adipocyte gene co-expressed in peripheral neurons,” Molecular and Cellular Endocrinology, vol. 276, no. 1-2, pp. 24–35, 2007.

[56] W. Liao, M. T. A. Nguyen, T. Yoshizaki, et al., “Suppression of PPAR-y attenuates insulin-stimulated glucose uptake by affecting both GLUT1 and GLUT4 in 3T3-L1 adipocytes,” American Journal of Physiology, vol. 293, no. 1, pp. E219–E227, 2007.

[57] L. J. Kelly, P. P. Vicario, G. M. Thompson, et al., “Peroxisome proliferator-activated receptors γ and α mediate in vivo regulation of uncoupling protein (UCP-1, UCP-2, UCP-3) gene expression,” Endocrinology, vol. 139, no. 12, pp. 4920–4927, 1998.

[58] P. Ferré, “The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity,” Diabetes, vol. 53, supplement 1, pp. S43–S50, 2004.

[59] R. M. Evans, G. D. Barish, and Y.-X. Wang, “PPARs and the complex journey to obesity,” Nature Medicine, vol. 10, no. 4, pp. 355–361, 2004.

[60] J. A. Akune, S. Ohba, S. Kamekura, et al., “PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” The Journal of Clinical Investigation, vol. 113, no. 6, pp. 846–855, 2004.

[61] S. H. Kim, C. I. Yoo, H. T. Kim, J. Y. Park, C. H. Kwon, and Y. K. Kim, “Activation of peroxisome proliferator-activated receptors γ and α in the bone marrow,” Annual Review of Medicine, vol. 55, pp. 495–506, 2004.

[62] T. Akune, S. Ohba, S. Kamekura, et al., “PPARγ insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” The Journal of Clinical Investigation, vol. 113, no. 6, pp. 846–855, 2004.
receptor-y (PPARy) induces cell death through MAPK-dependent mechanism in osteoblastic cells,” *Toxicology and Applied Pharmacology*, vol. 215, no. 2, pp. 198–207, 2006.

[63] T.-A. Cock, J. Back, F. Elefteriou, et al., “Enhanced bone formation in lipodystrophic PPARγ doubly heterozygous mice relocates haematopoiesis to the spleen,” *EMBO Reports*, vol. 5, no. 10, pp. 1007–1012, 2004.

[64] O. P. Lazarenko, S. O. Rzonca, L. J. Suva, and B. Lecka-Czernik, “Netoglitazone is a PPAR-gamma ligand with selective effects on bone and fat,” *Bone*, vol. 38, no. 1, pp. 74–84, 2006.

[65] A. A. Ali, R. S. Weinstein, S. A. Stewart, A. M. Parfitt, S. C. Manolagas, and R. L. Jilka, “Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation,” *Endocrinology*, vol. 146, no. 3, pp. 1226–1235, 2005.

[66] B. Lecka-Czernik, E. J. Moerman, D. F. Grant, J. M. Lehmann, S. C. Manolagas, and R. L. Jilka, “Divergent effects of selective peroxisome proliferator-activated receptor-y2 ligands on adipocyte versus osteoblast differentiation,” *Endocrinology*, vol. 143, no. 6, pp. 2376–2384, 2002.

[67] S. O. Rzonca, L. J. Suva, D. Gaddy, D. C. Montague, and B. Lecka-Czernik, “Bone is a target for the antidiabetic compound rosiglitazone,” *Endocrinology*, vol. 145, no. 1, pp. 401–406, 2004.

[68] J.-H. Hong, E. S. Hwang, M. T. McManus, et al., “TAZ, a transcriptional modulator of mesenchymal stem cell differentiation,” *Science*, vol. 309, no. 5737, pp. 1074–1078, 2005.

[69] M. Caron, M. Auclair, C. Viguouroux, M. Glorian, C. Forrest, and J. Capeau, “The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits adipocyte differentiation, and induces insulin resistance,” *Diabetes*, vol. 50, no. 6, pp. 1378–1388, 2001.

[70] M. Caron, M. Auclair, H. Sterlingot, M. Kornprobst, and J. Capeau, “Some HIV protease inhibitors alter lamin A/C maturation and stability, SREBP-1 nuclear localization and adipocyte differentiation,” *AIDS*, vol. 17, no. 17, pp. 2437–2444, 2003.

[71] Y. Tamori, J. Masugi, N. Nishino, and M. Kasuga, “Role of peroxisome proliferator-activated receptor-y in maintenance of the characteristics of mature 3T3-L1 adipocytes,” *Diabetes*, vol. 51, no. 7, pp. 2045–2055, 2002.

[72] O. Gavrilova, M. Haluzik, K. Matsusue, et al., “Liver peroxisome proliferator-activated receptor-y contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass,” *The Journal of Biological Chemistry*, vol. 278, no. 36, pp. 34268–34276, 2003.

[73] K. Kannisto, J. Sutinen, E. Korsheninnikova, et al., “Expression of adipogenic transcription factors, peroxisome proliferator-activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy,” *AIDS*, vol. 17, no. 12, pp. 1753–1762, 2003.

[74] I. Bogacka, H. Xie, G. A. Bray, and S. R. Smith, “The effect of pioglitazone on peroxisome proliferator-activated receptor-y target genes related to lipid storage in vivo,” *Diabetes Care*, vol. 27, no. 7, pp. 1660–1667, 2004.

[75] C. Hadigan, S. Yawetz, A. Thomas, F. Havers, P. E. Sax, and S. Grinspoon, “Metabolic effects of rosiglitazone in HIV lipodystrophy: a randomized, controlled trial,” *Annals of Internal Medicine*, vol. 140, no. 10, pp. 786–794, 2004.

[76] A. Carr, C. Workman, D. Carey, et al., “No effect of rosiglitazone for treatment of HIV-1 lipodystrophy: randomised, double-blind, placebo-controlled trial,” *The Lancet*, vol. 363, no. 9407, pp. 429–438, 2004.

[77] J. Sutinen, A.-M. Hakkinen, J. Westerbacka, et al., “Rosiglitazone in the treatment of HAART-associated lipodystrophy—a randomized double-blind placebo-controlled study,” *Antiviral Therapy*, vol. 8, no. 3, pp. 199–207, 2003.

[78] D. Kamin, C. Hadigan, M. Lehrke, S. Mazza, M. A. Lazar, and S. Grinspoon, “Resistin levels in human immunodeficiency virus-infected patients with lipodystrophy decrease in response to rosiglitazone,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 90, no. 6, pp. 3423–3426, 2005.

[79] J. P. H. van Wijk, E. J. P. de Koning, M. C. Cabezas, et al., “Comparison of rosiglitazone and metformin for treating HIV lipodystrophy: a randomized trial,” *Annals of Internal Medicine*, vol. 143, no. 5, pp. 337–346, 2005.

[80] S. Shrivastav, T. Kino, T. Cunningham, et al., “Human Immunodeficiency Virus (HIV-1) viral protein R suppresses transcriptional activity of peroxisome proliferator-activated receptor y and inhibits adipocyte differentiation: implications for HIV-associated lipodystrophy,” *Molecular Endocrinology*, vol. 22, no. 2, pp. 234–247, 2008.

[81] W. Paxton, R. I. Connor, and N. R. Landau, “Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis,” *Journal of Virology*, vol. 67, no. 12, pp. 7229–7237, 1993.

[82] N. K. Heinzinger, M. I. Bukrinsky, S. A. Haggerty, et al., “The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 91, no. 15, pp. 7311–7315, 1994.

[83] J. He, S. Choe, R. Walker, P. Di Marzio, D. O. Morgan, and N. R. Landau, “Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34(cdc2) activity,” *Journal of Virology*, vol. 69, no. 11, pp. 6705–6711, 1995.

[84] E. Jacotot, K. F. Ferri, C. El Hamel, et al., “Control of mitochondrial membrane permeabilization by adenosine nucleotide translocator interacting with HIV-1 viral protein R and Bcl-2,” *The Journal of Experimental Medicine*, vol. 193, no. 4, pp. 509–519, 2001.

[85] M. P. Sherman, C. M. C. De Noronha, D. Pearce, and W. C. Greene, “Human immunodeficiency virus type 1 Vpr contains two leucine-rich helices that mediate glucocorticoid receptor coactivation independently of its effects on G2 cell cycle arrest,” *Journal of Virology*, vol. 74, no. 17, pp. 8159–8165, 2000.

[86] T. Kino and G. P. Chrousos, “Virus-mediated modulation of the host endocrine signaling systems: clinical implications,” *Trends in Endocrinology and Metabolism*, vol. 18, no. 4, pp. 159–166, 2007.

[87] M. W.-H. Wang, S. Wei, R. Faccio, et al., “The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling,” *The Journal of Clinical Investigation*, vol. 114, no. 2, pp. 206–213, 2004.

[88] J. M. Fakruddin and J. Laurence, “HIV envelope gp120-induced signaling is impaired by interferon-γ/RANKL cross-talk,” *The Journal of Biological Chemistry*, vol. 278, no. 48, pp. 48251–48258, 2003.

[89] G. Pan, X. Wu, M. A. McKenna, X. Feng, T. R. Nagy, and J. M. McDonald, “AZT enhances osteoclastogenesis and bone loss,”
[90] G. Pan, M. Kilby, and J. M. McDonald, "Modulation of osteoclastogenesis induced by nucleoside reverse transcriptase inhibitors," *AIDS Research and Human Retroviruses*, vol. 22, no. 11, pp. 1131–1141, 2006.

[91] A. P. Malizia, E. J. Cotter, N. Chew, W. G. Powderly, and P. P. Doran, "HIV protease inhibitors selectively induce gene expression alterations associated with reduced calcium deposition in primary human osteoblasts," *AIDS Research and Human Retroviruses*, vol. 23, no. 2, pp. 243–250, 2007.

[92] E. J. Cotter, A. P. Malizia, N. Chew, W. G. Powderly, and P. P. Doran, "HIV proteins regulate bone marker secretion and transcription factor activity in cultured human osteoblasts with consequent potential implications for osteoblast function and development," *AIDS Research and Human Retroviruses*, vol. 23, no. 12, pp. 1521–1530, 2007.

[93] E. J. Cotter, H. S. M. Ip, W. G. Powderly, and P. P. Doran, "Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation," *BMC Musculoskeletal Disorders*, vol. 9, article 33, pp. 1–12, 2008.

[94] R. G. Jain and J. M. Lenhard, "Select HIV protease inhibitors alter bone and fat metabolism ex vivo," *The Journal of Biological Chemistry*, vol. 277, no. 22, pp. 19247–19250, 2002.